Your browser is no longer supported. Please, upgrade your browser.
Settings
BLUE bluebird bio, Inc. daily Stock Chart
BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-5.38 Insider Own0.70% Shs Outstand51.33M Perf Week0.23%
Market Cap8.97B Forward P/E- EPS next Y-7.86 Insider Trans-47.51% Shs Float49.71M Perf Month-10.36%
Income-229.60M PEG- EPS next Q-2.07 Inst Own- Short Float6.83% Perf Quarter-0.29%
Sales35.40M P/S253.39 EPS this Y25.40% Inst Trans0.15% Short Ratio3.97 Perf Half Y21.95%
Book/sh34.86 P/B5.01 EPS next Y5.70% ROA-23.00% Target Price222.35 Perf Year109.03%
Cash/sh25.13 P/C6.95 EPS next 5Y- ROE-28.10% 52W Range74.45 - 236.17 Perf YTD-1.88%
Dividend- P/FCF- EPS past 5Y17.50% ROI-12.70% 52W High-26.24% Beta2.15
Dividend %- Quick Ratio13.80 Sales past 5Y153.30% Gross Margin- 52W Low133.98% ATR9.92
Employees479 Current Ratio13.80 Sales Q/Q162.50% Oper. Margin- RSI (14)44.55 Volatility4.26% 5.92%
OptionableYes Debt/Eq0.10 EPS Q/Q87.10% Profit Margin- Rel Volume0.51 Prev Close174.75
ShortableYes LT Debt/Eq0.10 EarningsMay 23 AMC Payout- Avg Volume855.81K Price174.20
Recom2.20 SMA200.15% SMA50-10.36% SMA20012.88% Volume226,253 Change-0.31%
Mar-21-18Reiterated Morgan Stanley Equal-Weight $152 → $209
Mar-14-18Initiated Janney Neutral
Mar-05-18Initiated William Blair Outperform
Feb-22-18Reiterated Cantor Fitzgerald Underweight $122 → $113
Jan-25-18Downgrade Leerink Partners Outperform → Mkt Perform
Dec-21-17Initiated Oppenheimer Perform
Dec-13-17Reiterated Barclays Overweight $162 → $209
Dec-13-17Downgrade Maxim Group Buy → Hold $200
Dec-11-17Upgrade Jefferies Hold → Buy $130 → $211
Dec-11-17Reiterated Goldman Buy $186 → $309
Dec-11-17Reiterated Cantor Fitzgerald Underweight $58 → $113
Dec-05-17Initiated Canaccord Genuity Buy $202
Nov-30-17Reiterated Maxim Group Buy $170 → $200
Nov-06-17Downgrade Evercore ISI Outperform → In-line
Nov-03-17Upgrade Morgan Stanley Underweight → Equal-Weight
Nov-02-17Upgrade BTIG Research Neutral → Buy $177
Oct-16-17Upgrade Evercore ISI In-line → Outperform
Oct-11-17Resumed Jefferies Hold $126
Oct-09-17Reiterated Maxim Group Buy $100 → $170
Oct-06-17Resumed Goldman Buy $186
Apr-19-18 12:00AM  Gene Therapy Shows Promise in Patients with a Blood Disorder The Wall Street Journal
Apr-18-18 05:00PM  Gene Therapy Shows Promise in Patients with a Blood Disorder The Wall Street Journal
05:00PM  bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent -Thalassemia Business Wire
Apr-16-18 08:00AM  bluebird bio to Present at Alliance for Regenerative Medicines 6th Annual Cell & Gene Therapy Investor Day Business Wire
Apr-15-18 01:17PM  Is bluebird bio, Inc. a Buy on the Dip? Motley Fool
Apr-05-18 01:00PM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio Motley Fool
08:20AM  Todays Research Reports on Trending Tickers: Conatus Pharmaceuticals and bluebird bio ACCESSWIRE
06:00AM  4 Biotechs Ready for Big Rebounds Investopedia
Apr-04-18 09:15PM  3 Top Biotech Stocks to Buy in April Motley Fool +7.88%
Mar-29-18 11:00AM  Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate Zacks
Mar-28-18 01:09PM  Celgene Shares Higher on Co-Development Pact With Bluebird TheStreet.com
08:00AM  bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States Business Wire
Mar-21-18 09:00AM  This Is My Favorite Biotech Stock To Buy On Sale Motley Fool
Mar-14-18 09:53AM  Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued Benzinga
Mar-13-18 07:57AM  Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics Zacks
Mar-12-18 08:40AM  Blog Exposure - InflaRx Enrolled First Patient in Phase-IIb Trial of Lead Candidate IFX-1 in Hidradenitis Suppurativa ACCESSWIRE
Mar-11-18 10:31PM  bluebird bio Inc (BLUE), Iqvia Holdings Inc (IQV): Four Biotech Stocks to Buy Now Insider Monkey
Mar-07-18 08:00AM  bluebird bio to Present at Investor Conferences in March Business Wire
Mar-05-18 02:44PM  William Blair: Bluebird Bio Could See Another 'Blue Ribbon Year' In 2018 Benzinga
Feb-27-18 11:30PM  Why Oppenheimer Global fund is focusing on biotech as rates rise Reuters
Feb-26-18 08:12AM  Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio Zacks
Feb-23-18 07:09PM  3 Big Drugmakers Boosting Huge R&D Budgets Motley Fool
Feb-22-18 06:07PM  bluebird bio Updates Plans for the Year Ahead Motley Fool
Feb-21-18 05:51PM  Bluebird reports 4Q loss Associated Press
04:05PM  bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress Business Wire
Feb-17-18 10:31AM  How Celgene Hopes to Cash In on CAR-T Motley Fool
Feb-14-18 08:00AM  bluebird bio Appoints Alison Finger as Chief Commercial Officer Business Wire
Feb-06-18 05:10PM  Here's Why bluebird bio Soared 15% in January Motley Fool
Feb-05-18 12:39PM  Here's Why Global Blood Therapeutics Inc. Soared 47.1% in January Motley Fool
Feb-02-18 08:00AM  bluebird bio to Present at LEERINK Partners Global Healthcare Conference Business Wire
Jan-31-18 07:40AM  Recent Analysis Shows Forward Industries, Sigma Designs, Northeast, bluebird bio, Walker & Dunlop, and Atmos Energy Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jan-30-18 02:35PM  Celgene Looking Good With Plans for More Growth Motley Fool
Jan-26-18 10:53AM  Analysts Take Action on Abbott and Bluebird Bio GuruFocus.com
10:30AM  5 Biotechs That May Surge On Takeovers Investopedia
Jan-25-18 10:24AM  Leerink: Bluebird Bio's Catalysts Are Priced In Benzinga
Jan-24-18 02:35PM  Behind Celgenes Strategy in the Juno Therapeutics Acquisition Market Realist
Jan-23-18 09:39AM  Bluebird Up on Buyout Speculation After Celgene/Juno Deal Zacks
08:00AM  Celgene's Investments Are Soaring Motley Fool
07:31AM  These 3 Stocks Have Doubled Investors' Money Motley Fool
Jan-22-18 02:05PM  Why bluebird bio Is Soaring 11.9% Today Motley Fool +10.63%
02:00PM  Bluebird Bio Shouldn't Be Blue Bloomberg
11:23AM  Biotech M&A takes off as Sanofi and Celgene spend $20 billion Reuters
Jan-17-18 07:30AM  Could Little Known Orgenesis (ORGS) Become A Dominant Player in The Multi Billion Dollar Cell Therapy Market? ACCESSWIRE +7.28%
Jan-14-18 09:00AM  5 Biotech Stocks That Could Be Bought Out in 2018 Motley Fool
Jan-11-18 07:31PM  What bluebird bio Wants You to Know About Its Business Motley Fool
08:00AM  Up 188.7%, Is bluebird bio. Stock Still a Strong Buy? Motley Fool
Jan-08-18 04:05PM  bluebird bio Announces Closing of Over-Allotment Option in Public Offering Business Wire
Jan-02-18 04:22PM  Here's How bluebird bio, Inc. Crushed It in 2017 Motley Fool
Dec-28-17 11:46AM  2018 Should Be Better for Celgene Corporation and CELG Stock InvestorPlace
Dec-21-17 04:15PM  bluebird bio to Present at Investor Conferences in January Business Wire
Dec-20-17 06:32AM  What to Expect From Celgene Corporation in 2018 Motley Fool
Dec-19-17 11:02AM  Celgene Stock Up Huge On Exciting CAR-T News Motley Fool
11:02AM  Celgene Shareholders Excited by CAR-T News Motley Fool
Dec-15-17 06:15PM  Bluebird Bio Inc (BLUE) President and CEO Nick Leschly Sold $21.6 million of Shares GuruFocus.com
Dec-13-17 04:09PM  This Biotech Stock Seen As Cheapest Among Rivals In Cancer Drugs Investor's Business Daily
12:31PM  ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More Benzinga
11:30AM  Bluebird Bio Stumbles Over Secondary Offering 24/7 Wall St.
10:24AM  Analyst Doubts Bluebird Bio Shares Up 200% In 2017 Can Fly Much Higher Benzinga
08:00AM  Here's Why Everyone's So Excited About bluebird bio Motley Fool
07:31AM  5 Biotech Buyout Candidates for 2018 Motley Fool
Dec-12-17 08:46PM  bluebird bio Announces Pricing of Public Offering of Common Stock Business Wire -5.38%
02:28PM  10 Biggest Stock Market Successes of 2017 InvestorPlace
12:52PM  ETFs with exposure to bluebird bio, Inc. : December 12, 2017 Capital Cube
Dec-11-17 05:08PM  What Happened in the Stock Market Today Motley Fool +17.91%
05:00PM  4 Stocks Move to Start the Week GuruFocus.com
04:26PM  Apple and Chesapeake Energy rise; Spark Therapeutics sinks Associated Press
04:19PM  Bluebird Bio stock retreats from records after announcing stock offering MarketWatch
04:01PM  bluebird bio Announces Proposed Public Offering of Common Stock Business Wire
03:30PM  Bluebird Bio rallies, Spark Therapeutics craters after unveiling data at ASH meeting MarketWatch
02:25PM  Life-Shortening Blood Disease Gets Rush of Research Bloomberg
01:45PM  Spark Therapeutics' gene therapy program brings stock dow... CNBC Videos
01:43PM  Bluebird could be on the way to a cure for sickle cell disease CNBC
12:42PM  Goldman: Bluebird Bio Is One Step Closer To A Sickle Cell Cure Benzinga
12:23PM  Bluebird Bio Becoming Household Name With This Promising Cancer Treatment TheStreet.com
12:06PM  Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today Zacks
11:47AM  Bluebird Bio gives hope to cancer patients CNBC Videos
11:27AM  Biotech winners and losers: ASH Hematology Conference CNBC Videos
10:53AM  Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting Benzinga
10:34AM  Stocks Trade Higher Following Explosion at New York's Port Authority TheStreet.com
10:21AM  Despite Bluebird Bio's 17% Rally, Another 55% Surge Could Be Coming TheStreet.com
09:40AM  Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers TheStreet.com
09:19AM  After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target Benzinga
09:15AM  bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results Motley Fool
09:05AM  Highlights from ASH Sent bluebird Bio Inc (BLUE) Shares Skyrocketing; J.P. Morgan Cheers SmarterAnalyst
09:05AM  Morning Movers: Bluebird Bio, Solar Stocks Soar; Paccar Falls Barrons.com
09:00AM  bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent -Thalassemia at American Society of Hematology Annual Meeting Business Wire
08:32AM  Bluebird Bio shares soar 24% premarket as Goldman raises price target to $309 from $186 MarketWatch
Dec-10-17 04:30PM  bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent -Thalassemia at American Society of Hematology Annual Meeting Business Wire
04:30PM  bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting Business Wire
10:30AM  Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting Business Wire
10:30AM  Bluebird, Celgene Myeloma Therapy Appears to Improve in Time Bloomberg
Dec-07-17 08:00AM  bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy Business Wire +5.33%
07:31AM  Here's Why bluebird bio's Shares Soared 24% in November Motley Fool
Dec-05-17 09:58AM  Bluebird Bio (BLUE) Bullish Camp Just Got Stronger SmarterAnalyst
Nov-30-17 07:30AM  Are Viruses a Problem for CAR-T Drugmakers? Motley Fool
Nov-29-17 08:03AM  A Virus Shortage? BlueBird Bio Buys A Factory To Make Its Own Forbes
08:00AM  bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients Business Wire
Nov-27-17 12:22PM  ETFs with exposure to bluebird bio, Inc. : November 27, 2017 Capital Cube
Nov-22-17 08:30AM  New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-20-17 10:12AM  The Forbes Healthcare Summit: The Final Agenda Forbes
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davidson DavidChief Medical OfficerApr 12Option Exercise24.473,00073,41027,905Apr 16 04:48 PM
Davidson DavidChief Medical OfficerApr 12Sale180.173,000540,50824,905Apr 16 04:48 PM
Davidson DavidChief Medical OfficerApr 02Option Exercise24.4722,000538,34046,905Apr 04 04:47 PM
Gregory Philip DChief Scientific OfficerApr 02Option Exercise50.511,25063,13831,522Apr 04 04:50 PM
Davidson DavidChief Medical OfficerApr 02Sale167.5222,0003,685,38724,905Apr 04 04:47 PM
Gregory Philip DChief Scientific OfficerApr 02Sale168.712,250379,60829,272Apr 04 04:50 PM
Vachon MarkDirectorMar 15Option Exercise30.476,000182,8207,000Mar 19 04:06 PM
Vachon MarkDirectorMar 15Sale214.386,0001,286,2501,000Mar 19 04:06 PM
Davidson DavidChief Medical OfficerMar 02Option Exercise5.504,00022,00228,905Mar 06 04:29 PM
Davidson DavidChief Medical OfficerMar 02Sale201.194,000804,75124,905Mar 06 04:29 PM
Gregory Philip DChief Scientific OfficerMar 01Option Exercise50.511,25063,13832,522Mar 05 05:14 PM
Gregory Philip DChief Scientific OfficerMar 01Sale200.002,250449,99530,272Mar 05 05:14 PM
HIGH SUSANNA GATTIChief Operating OfficerFeb 28Option Exercise68.651,04471,67118,544Mar 02 04:01 PM
HIGH SUSANNA GATTIChief Operating OfficerFeb 28Sale202.671,044211,59217,500Mar 02 04:01 PM
Davidson DavidChief Medical OfficerFeb 02Option Exercise5.504,00022,00228,905Feb 05 04:01 PM
Davidson DavidChief Medical OfficerFeb 02Sale202.364,000809,44124,905Feb 05 04:01 PM
Gregory Philip DChief Scientific OfficerFeb 01Option Exercise50.511,25063,13833,522Feb 05 04:02 PM
Gregory Philip DChief Scientific OfficerFeb 01Sale204.902,250461,02031,272Feb 05 04:02 PM
Cole JasonChief Legal OfficerJan 30Option Exercise22.5325,000563,25044,798Feb 01 04:30 PM
HIGH SUSANNA GATTIChief Operating OfficerJan 30Option Exercise68.6514,7941,015,60828,512Feb 01 04:31 PM
Cole JasonChief Legal OfficerJan 30Sale195.9125,0004,897,74319,798Feb 01 04:30 PM
HIGH SUSANNA GATTIChief Operating OfficerJan 30Sale195.9117,2623,381,79211,250Feb 01 04:31 PM
Davidson DavidChief Medical OfficerJan 08Option Exercise5.501,2006,60014,855Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 08Sale174.071,200208,88313,655Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 05Sale173.382,322402,57913,655Jan 09 04:05 PM
Cole JasonChief Legal OfficerJan 05Sale173.381,129195,74119,798Jan 09 04:05 PM
Walsh Jeffrey T.Chief FinancialJan 05Sale173.383,060530,53024,245Jan 09 04:07 PM
Leschly NickPresident and CEOJan 05Sale173.385,435942,298170,297Jan 09 04:06 PM
Gregory Philip DChief Scientific OfficerJan 05Sale173.381,712296,82023,772Jan 09 04:06 PM
Davidson DavidChief Medical OfficerJan 03Option Exercise5.506,00033,00221,977Jan 05 04:10 PM
Gregory Philip DChief Scientific OfficerJan 03Option Exercise50.511,25063,13827,734Jan 05 04:11 PM
Davidson DavidChief Medical OfficerJan 03Sale180.306,0001,081,78115,977Jan 05 04:10 PM
Gregory Philip DChief Scientific OfficerJan 03Sale180.692,250406,55025,484Jan 05 04:11 PM
Leschly NickPresident and CEODec 13Option Exercise5.5037,873208,317293,232Dec 15 04:09 PM
Leschly NickPresident and CEODec 13Sale184.08117,50021,629,119175,732Dec 15 04:09 PM
Vachon MarkDirectorDec 11Option Exercise30.476,000182,8208,000Dec 13 04:10 PM
Walsh Jeffrey T.Chief FinancialDec 11Option Exercise24.479,900242,25337,205Dec 13 04:09 PM
Vachon MarkDirectorDec 11Sale216.647,0001,516,4651,000Dec 13 04:10 PM
Walsh Jeffrey T.Chief FinancialDec 11Sale216.549,9002,143,78527,305Dec 13 04:09 PM
Gregory Philip DChief Scientific OfficerDec 01Option Exercise50.511,25063,13828,734Dec 05 04:08 PM
Davidson DavidChief Medical OfficerDec 01Option Exercise5.504,00022,00219,977Dec 05 04:08 PM
Gregory Philip DChief Scientific OfficerDec 01Sale172.542,250388,21126,484Dec 05 04:08 PM
Davidson DavidChief Medical OfficerDec 01Sale172.424,000689,67915,977Dec 05 04:08 PM
HIGH SUSANNA GATTIChief Operating OfficerDec 01Sale172.151,282220,69613,718Dec 05 04:09 PM
Walsh Jeffrey T.Chief FinancialNov 10Option Exercise19.999,900197,87037,205Nov 14 04:02 PM
Walsh Jeffrey T.Chief FinancialNov 10Sale149.589,9001,480,86527,305Nov 14 04:02 PM
Gregory Philip DChief Scientific OfficerNov 01Option Exercise50.511,25063,13829,734Nov 03 04:07 PM
Walsh Jeffrey T.Chief FinancialNov 01Option Exercise5.5035,000192,51462,305Nov 03 04:08 PM
Leschly NickPresident and CEONov 01Option Exercise5.502,12711,699257,486Nov 03 04:08 PM
Davidson DavidChief Medical OfficerNov 01Option Exercise5.504,00022,00219,977Nov 03 04:06 PM
Gregory Philip DChief Scientific OfficerNov 01Sale144.312,250324,69027,484Nov 03 04:07 PM
Walsh Jeffrey T.Chief FinancialNov 01Sale151.3835,0005,298,32627,305Nov 03 04:08 PM
Leschly NickPresident and CEONov 01Sale145.172,127308,779255,359Nov 03 04:08 PM
Davidson DavidChief Medical OfficerNov 01Sale145.214,000580,82215,977Nov 03 04:06 PM
Leschly NickPresident and CEOOct 23Sale145.263,700537,455255,359Oct 24 04:17 PM
Leschly NickPresident and CEOOct 20Sale145.023,350485,813259,059Oct 24 04:17 PM
Leschly NickPresident and CEOOct 17Sale145.0510,8231,569,840262,409Oct 19 04:13 PM
Walsh Jeffrey T.Chief FinancialOct 10Option Exercise5.504,90026,95232,205Oct 11 04:37 PM
Walsh Jeffrey T.Chief FinancialOct 10Sale129.944,900636,72427,305Oct 11 04:37 PM
Gregory Philip DChief Scientific OfficerOct 02Option Exercise50.511,25063,13830,734Oct 04 04:02 PM
Davidson DavidChief Medical OfficerOct 02Option Exercise5.504,00022,00219,977Oct 04 04:02 PM
Davidson DavidChief Medical OfficerOct 02Sale131.314,000525,24915,977Oct 04 04:02 PM
Gregory Philip DChief Scientific OfficerOct 02Sale131.822,250296,60228,484Oct 04 04:02 PM
MARAGANORE JOHNDirectorSep 14Option Exercise2.0918,86839,43424,711Sep 18 04:09 PM
MARAGANORE JOHNDirectorSep 14Sale131.2118,8682,475,7335,843Sep 18 04:09 PM
Vachon MarkDirectorSep 12Option Exercise30.476,000182,8208,000Sep 14 04:09 PM
Vachon MarkDirectorSep 12Sale126.826,000760,9232,000Sep 14 04:09 PM
Walsh Jeffrey T.Chief FinancialSep 11Option Exercise5.504,90026,95232,205Sep 13 04:07 PM
Walsh Jeffrey T.Chief FinancialSep 11Sale125.734,900616,06527,305Sep 13 04:07 PM
Leschly NickPresident and CEOSep 01Option Exercise5.506,36435,005295,732Sep 05 04:01 PM
Gregory Philip DChief Scientific OfficerSep 01Option Exercise50.511,25063,13831,734Sep 06 04:06 PM
Davidson DavidChief Medical OfficerSep 01Option Exercise5.5012,00066,00527,977Sep 06 04:06 PM
Davidson DavidChief Medical OfficerSep 01Sale129.0812,0001,548,90415,977Sep 06 04:06 PM
Gregory Philip DChief Scientific OfficerSep 01Sale126.062,250283,63529,484Sep 06 04:06 PM
Leschly NickPresident and CEOSep 01Sale130.0422,5002,925,983273,232Sep 05 04:01 PM
Walsh Jeffrey T.Chief FinancialAug 31Option Exercise5.5012,00066,00539,305Sep 05 04:02 PM
Schenkein David PDirectorAug 31Option Exercise8.162,00016,3125,176Sep 05 04:02 PM
LYNCH DANIELDirectorAug 31Option Exercise5.505002,7503,300Sep 05 04:01 PM
LYNCH DANIELDirectorAug 31Sale120.0050060,0002,800Sep 05 04:01 PM
Schenkein David PDirectorAug 31Sale115.072,000230,1453,176Sep 05 04:02 PM
Walsh Jeffrey T.Chief FinancialAug 31Sale125.0112,0001,500,09127,305Sep 05 04:02 PM
Leschly NickPresident and CEOAug 31Sale115.0924,3332,800,461289,368Sep 05 04:01 PM
Leschly NickPresident and CEOAug 30Sale115.1825,6672,956,307313,701Aug 31 04:16 PM
Walsh Jeffrey T.Chief FinancialAug 28Option Exercise5.501,2506,87628,555Aug 30 04:17 PM
Walsh Jeffrey T.Chief FinancialAug 28Sale107.061,250133,82627,305Aug 30 04:17 PM
MARAGANORE JOHNDirectorAug 24Option Exercise2.0913,83928,92419,682Aug 28 04:17 PM
MARAGANORE JOHNDirectorAug 24Sale95.8111,0851,062,1088,597Aug 28 04:17 PM
Mandell JamesDirectorAug 14Sale95.951,00095,9501,000Aug 15 04:05 PM
Walsh Jeffrey T.Chief FinancialAug 10Option Exercise5.501,2506,87628,555Aug 14 04:03 PM
Walsh Jeffrey T.Chief FinancialAug 10Sale95.411,250119,26527,305Aug 14 04:03 PM
Gregory Philip DChief Scientific OfficerAug 07Option Exercise50.5150025,25531,234Aug 09 04:01 PM
Gregory Philip DChief Scientific OfficerAug 07Sale99.0075074,25030,484Aug 09 04:01 PM
Sullivan EricPrincipal Accounting OfficerAug 04Option Exercise53.6844523,8906,119Aug 07 04:02 PM
Sullivan EricPrincipal Accounting OfficerAug 04Sale95.2144542,3705,674Aug 07 04:02 PM
Sullivan EricPrincipal Accounting OfficerAug 03Option Exercise22.204169,2376,090Aug 07 04:02 PM
Sullivan EricPrincipal Accounting OfficerAug 03Sale92.3541638,4185,674Aug 07 04:02 PM
MARAGANORE JOHNDirectorAug 02Sale96.742,754266,4255,843Aug 28 04:17 PM
Gregory Philip DChief Scientific OfficerAug 01Option Exercise50.5175037,88332,234Aug 03 04:04 PM
Davidson DavidChief Medical OfficerAug 01Option Exercise2.093,0006,27018,977Aug 03 04:04 PM
Davidson DavidChief Medical OfficerAug 01Sale92.373,000277,09915,977Aug 03 04:04 PM